A First in human study of TD-8236, a novel inhaled JAK inhibitor

Trial Profile

A First in human study of TD-8236, a novel inhaled JAK inhibitor

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs TD 8236 (Primary)
  • Indications Respiration disorders
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 01 Aug 2018 According to a Theravance Biopharma media release, this study is expected to study in late 2018.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top